Cargando…

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects

INTRODUCTION: Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic NSCLC and management of immunotherapy-related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI because of irAEs is a frequent clinical dilemma with limited available...

Descripción completa

Detalles Bibliográficos
Autores principales: Lievense, Lysanne A., Heukels, Peter, van Walree, Nico C., van der Leest, Cor H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791802/
https://www.ncbi.nlm.nih.gov/pubmed/36578272
http://dx.doi.org/10.1016/j.jtocrr.2022.100441
_version_ 1784859494201688064
author Lievense, Lysanne A.
Heukels, Peter
van Walree, Nico C.
van der Leest, Cor H.
author_facet Lievense, Lysanne A.
Heukels, Peter
van Walree, Nico C.
van der Leest, Cor H.
author_sort Lievense, Lysanne A.
collection PubMed
description INTRODUCTION: Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic NSCLC and management of immunotherapy-related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI because of irAEs is a frequent clinical dilemma with limited available data. METHODS: This single-center retrospective observational study reviewed the clinical course of 30 patients with metastatic NSCLC in whom ICI had to be discontinued owing to a serious irAE after an initial objective response to therapy. RESULTS: After ICI discontinuation, 14 patients (47%) developed a durable response of more than 6 months, seven patients (23%) developed oligoprogression treated with local radiotherapy leading to disease control, six patients (20%) had progression of disease within 6 months, and three patients (10%) died owing to a severe irAE. CONCLUSIONS: A watchful waiting approach is justified after discontinuation of ICI owing to irAEs in patients with metastatic NSCLC with an initial response to therapy.
format Online
Article
Text
id pubmed-9791802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97918022022-12-27 Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects Lievense, Lysanne A. Heukels, Peter van Walree, Nico C. van der Leest, Cor H. JTO Clin Res Rep Brief Report INTRODUCTION: Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic NSCLC and management of immunotherapy-related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI because of irAEs is a frequent clinical dilemma with limited available data. METHODS: This single-center retrospective observational study reviewed the clinical course of 30 patients with metastatic NSCLC in whom ICI had to be discontinued owing to a serious irAE after an initial objective response to therapy. RESULTS: After ICI discontinuation, 14 patients (47%) developed a durable response of more than 6 months, seven patients (23%) developed oligoprogression treated with local radiotherapy leading to disease control, six patients (20%) had progression of disease within 6 months, and three patients (10%) died owing to a severe irAE. CONCLUSIONS: A watchful waiting approach is justified after discontinuation of ICI owing to irAEs in patients with metastatic NSCLC with an initial response to therapy. Elsevier 2022-11-25 /pmc/articles/PMC9791802/ /pubmed/36578272 http://dx.doi.org/10.1016/j.jtocrr.2022.100441 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Report
Lievense, Lysanne A.
Heukels, Peter
van Walree, Nico C.
van der Leest, Cor H.
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
title Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
title_full Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
title_fullStr Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
title_full_unstemmed Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
title_short Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
title_sort clinical outcomes of patients with metastatic nsclc after discontinuation of immunotherapy because of immune-related adverse effects
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791802/
https://www.ncbi.nlm.nih.gov/pubmed/36578272
http://dx.doi.org/10.1016/j.jtocrr.2022.100441
work_keys_str_mv AT lievenselysannea clinicaloutcomesofpatientswithmetastaticnsclcafterdiscontinuationofimmunotherapybecauseofimmunerelatedadverseeffects
AT heukelspeter clinicaloutcomesofpatientswithmetastaticnsclcafterdiscontinuationofimmunotherapybecauseofimmunerelatedadverseeffects
AT vanwalreenicoc clinicaloutcomesofpatientswithmetastaticnsclcafterdiscontinuationofimmunotherapybecauseofimmunerelatedadverseeffects
AT vanderleestcorh clinicaloutcomesofpatientswithmetastaticnsclcafterdiscontinuationofimmunotherapybecauseofimmunerelatedadverseeffects